Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone (standard first-line treatment) and intralesional Candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 6
Healthy Volunteers: f
View:
• Diagnosis of alopecia areata
• SALT score of less than 50% extension
• Has not received any topical or systemic treatment in the last month
• Signed informed consent
Locations
Other Locations
Mexico
Hospital Universitario Dr. José Eleuterio González
RECRUITING
Monterrey
Contact Information
Primary
Erika Alba-Rojas, MD
eri9ar@yahoo.com
+528183891111
Time Frame
Start Date: 2024-08-20
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 30
Treatments
Active_comparator: intralesional Triamcinolone
Triamcinolone acetonide will be administered intralesionally at a concentration of 4 mg/mL. The solution will be injected in 0.1 mL doses, spaced 1 cm apart. The maximum total dose per session will be limited to 3 mL
Experimental: Candida albicans antigen
Single subcutaneous administration of 0.1 mL of Candida albicans antigen into one of the alopecic patches
Related Therapeutic Areas
Sponsors
Leads: Universidad Autonoma de Nuevo Leon